Cardinal Health (NYSE:CAH) CAO Mary Scherer Sells 2,302 Shares of Stock

Cardinal Health, Inc. (NYSE:CAH) CAO Mary Scherer sold 2,302 shares of the stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $237.39, for a total transaction of $546,471.78. Following the sale, the chief accounting officer directly owned 2,811 shares of the company’s stock, valued at approximately $667,303.29. This represents a 45.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Cardinal Health Price Performance

CAH stock opened at $228.95 on Friday. The company’s 50 day simple moving average is $231.91 and its 200-day simple moving average is $217.78. The firm has a market capitalization of $53.25 billion, a P/E ratio of 31.67, a P/E/G ratio of 1.26 and a beta of 0.49. Cardinal Health, Inc. has a 52-week low of $145.87 and a 52-week high of $258.30.

Cardinal Health (NYSE:CAH) last released its quarterly earnings data on Tuesday, August 11th. The company reported $2.91 earnings per share for the quarter, beating the consensus estimate of $2.42 by $0.49. The firm had revenue of $63.67 billion for the quarter, compared to analyst estimates of $65.15 billion. Cardinal Health had a net margin of 0.67% and a negative return on equity of 98.53%. The company’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.08 EPS. Cardinal Health has set its FY 2027 guidance at 12.400-12.600 EPS. Sell-side analysts predict that Cardinal Health, Inc. will post 12.54 EPS for the current fiscal year.

Cardinal Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Thursday, October 1st will be issued a dividend of $0.5158 per share. This represents a $2.06 annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend is Thursday, October 1st. Cardinal Health’s dividend payout ratio (DPR) is presently 28.49%.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on CAH. UBS Group raised their price target on Cardinal Health from $274.00 to $280.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. Morgan Stanley upped their price objective on shares of Cardinal Health from $255.00 to $265.00 and gave the company an “overweight” rating in a research report on Wednesday, August 12th. William Blair started coverage on Cardinal Health in a research report on Tuesday, April 28th. They set an “outperform” rating for the company. Evercore reiterated an “outperform” rating and issued a $270.00 target price on shares of Cardinal Health in a research note on Wednesday, August 12th. Finally, Bank of America raised their price objective on shares of Cardinal Health from $240.00 to $260.00 and gave the stock a “buy” rating in a research report on Thursday, July 2nd. Sixteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $266.56.

Key Headlines Impacting Cardinal Health

Here are the key news stories impacting Cardinal Health this week:

• Positive Sentiment: Royal Bank of Canada initiated coverage with an “outperform” rating and a $276 price target, citing Cardinal Health’s integration of higher-margin services as a potential driver of earnings outperformance. RBC initiates Cardinal Health coverage
• Positive Sentiment: Analysts maintain a broadly constructive view, with Cardinal Health carrying a consensus “moderate buy” rating and an average price target of approximately $266.56. Zacks also highlighted CAH as a potential long-term value stock. Zacks Cardinal Health value-stock analysis
• Neutral Sentiment: Cardinal Health recently declared a quarterly dividend of $0.5158 per share, equivalent to an annualized $2.06 payout and a yield of roughly 0.9%. The dividend provides modest income support but is unlikely to be a major near-term catalyst.
• Negative Sentiment: Several senior executives sold substantial positions near $235–$237. Jason Hollar sold 124,529 shares worth about $29.4 million, while Deborah Weitzman sold 7,354 shares worth approximately $1.7 million. Additional sales by other insiders significantly reduced their holdings, potentially signaling profit-taking after the stock’s strong advance. Cardinal Health insider sales
• Negative Sentiment: Cardinal Health’s quarterly adjusted EPS of $2.91 beat the $2.42 consensus estimate, but an analysis said a significant portion of the improvement came from a one-time tariff refund. Investors may therefore question whether the earnings growth can be sustained. Cardinal Health earnings analysis

Hedge Funds Weigh In On Cardinal Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Integrated Wealth Concepts LLC boosted its position in shares of Cardinal Health by 6.9% during the 1st quarter. Integrated Wealth Concepts LLC now owns 4,363 shares of the company’s stock valued at $601,000 after purchasing an additional 280 shares in the last quarter. Jones Financial Companies Lllp increased its position in Cardinal Health by 198.3% in the first quarter. Jones Financial Companies Lllp now owns 21,112 shares of the company’s stock worth $27,000 after buying an additional 14,034 shares during the last quarter. Arrowstreet Capital Limited Partnership purchased a new stake in shares of Cardinal Health during the second quarter worth $1,935,000. Cerity Partners LLC grew its position in shares of Cardinal Health by 17.0% during the 2nd quarter. Cerity Partners LLC now owns 40,426 shares of the company’s stock valued at $6,792,000 after purchasing an additional 5,880 shares in the last quarter. Finally, Nebula Research & Development LLC raised its position in shares of Cardinal Health by 34.4% during the 2nd quarter. Nebula Research & Development LLC now owns 10,334 shares of the company’s stock valued at $1,736,000 after buying an additional 2,646 shares in the last quarter. 87.17% of the stock is currently owned by institutional investors and hedge funds.

About Cardinal Health

Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.

The company’s core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.